Mirum Pharmaceuticals’ Ctexli (chenodiol) has gained US Food and Drug Administration (FDA) approval for treating adults with cerebrotendinous xanthomatosis (CTX), a rare lipid storage disease. It is ...

The Food and Drug Administration has approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis in adults.

The US Food and Drug Administration (FDA) late Friday revealed it has approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Developed by Mirum ...

Ctexli 250mg 3 times daily showed significant reductions in plasma cholestanol and urine 23S-pentol compared with placebo. The Food and Drug Administration (FDA) has approved Ctexli ™ (chenodiol ...

US Food and Drug Administration (FDA) has approved Ctexli (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Ctexli is the first and only ...

“Cerebrotendinous xanthomatosis (CTX) is a rare disease that can present with early cataracts, tendon lipid deposits, and significant neurologic disease, and the latter may be prevented with ...

Feb. 21, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA ...

The Food and Drug Administration approved Ctexli for the treatment of cerebrotendinous xanthomatosis in adults. “Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage ...